Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Inclusion Criteria: * Male, Caucasian subjects aged between 18-40 years (inclusive) * Healthy subjects as determined by medical history, physical examination * Body weight between 70 - 100 kg and BMI between 19 and 29 kg/m2, extremes incl * ECG recording based on a 12-lead ECG which is normal (PR \< 210 ms, QRS \<110 ms, QTC 380 -430 ms) or contains only slight deviations * Normal vital signs (after 5 minutes resting), blood pressure values (systolic \> or equal to 100 and \< or equal to 140 mmHg, diastolic \> or equal to 50 and \< or equal to 90 mmHg), heart rate between 45 and 90 beats per minute (bpm), body temperature \< 37.5°C * Subjects who are able and willing to give written informed consent * Normal white blood cell count, CRP and IL-6 at screening and Day -1 * Subjects must be using two acceptable methods for contraception (e.g. spermicide and condom) during the study and refrain from fathering a child in the 3 months following dosing Exclusion Criteria: * In the opinion of the investigator subjects with clinically significant history or presence of cardiovascular, respiratory, renal, hepatic, metabolic, endocrinological, gastrointestinal, hematological, neurological, dermatological, psychiatric diseases, cancer or other major diseases; * Infection or known inflammatory process; * Known autoimmune diseases or immunodeficiency or known family history of autoimmune diseases or immunodeficiency; * Clinical significant allergic disease; * Known serum hepatitis or who are carriers of the Hepatitis B surface antigen or Hepatitis C antibodies or with a positive result to the test for HIV 1/2 antibodies; * Subjects who have received an investigational drug and/or a vaccination within 3 months prior to start of the treatment in study and those who anticipate receipt of a vaccine within 2 months after the last dose of study drug; * Subjects, who have received prior treatment within 1 year with monoclonal antibodies or other biologic agents; * The use of any concomitant prescription or non-prescription medication within 14 days prior to the first administration of study medication until follow-up; or treatment with medication that may affect immune function (e.g. immunoglobulins, corticosteroids) within 6 months before dosing; * Donation of blood (\>400 ml) or blood products within the last 3 months prior to admission to the clinical unit or plasmapheresis within 4 weeks prior to study start; * Definite or suspected personal history of adverse reactions or hypersensitivity to drugs especially to the ingredients of the trial compound or to compounds with a similar structure; * Use of more than 5 cups or glasses of coffee, tea and / or cola per day; * Presence or history of drug and/or alcohol abuse or an average daily intake of more than 20 g alcohol per day; * Positive test for alcohol or drugs at screening and/or on Day -1; * Smokers of \> 5 cigarettes/day or equivalent; * Subjects who are unlikely to be compliant and attend scheduled clinic visits as required; * Participation in this study on a previous dose level